These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 3994898)

  • 1. An investigation of the cause of accumulation of verapamil during regular dosing in patients.
    Schwartz JB; Abernethy DR; Taylor AA; Mitchell JR
    Br J Clin Pharmacol; 1985 Apr; 19(4):512-6. PubMed ID: 3994898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of verapamil in patients with hypertension.
    Anderson P; Bondesson U; de Faire U
    Eur J Clin Pharmacol; 1986; 31(2):155-63. PubMed ID: 3803414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolongation of verapamil elimination kinetics during chronic oral administration.
    Schwartz JB; Keefe DL; Kirsten E; Kates RE; Harrison DC
    Am Heart J; 1982 Aug; 104(2 Pt 1):198-203. PubMed ID: 7102502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced verapamil clearance during long-term oral administration.
    Shand DG; Hammill SC; Aanonsen L; Pritchett EL
    Clin Pharmacol Ther; 1981 Nov; 30(5):701-6. PubMed ID: 7297027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma levels and urinary excretion of verapamil, norverapamil, N-dealkylverapamil (D617), N-dealkylnorverapamil (D620) following oral administration of a slow-release preparation.
    Barbieri E; Padrini R; Piovan D; Toffoli M; Cargnelli G; Trevi G; Ferrari M
    Int J Clin Pharmacol Res; 1985; 5(2):99-107. PubMed ID: 4018947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Verapamil and norverapamil plasma levels in infants and children during chronic oral treatment.
    Piovan D; Padrini R; Svalato Moreolo G; Magnolfi G; Milanesi O; Zordan R; Pellegrino PA; Ferrari M
    Ther Drug Monit; 1995 Feb; 17(1):60-7. PubMed ID: 7725379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo comparison of putative probes of CYP3A4/5 activity: erythromycin, dextromethorphan, and verapamil.
    Krecic-Shepard ME; Barnas CR; Slimko J; Gorski JC; Wainer IW; Schwartz JB
    Clin Pharmacol Ther; 1999 Jul; 66(1):40-50. PubMed ID: 10430108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of verapamil and norverapamil during long-term oral therapy.
    Tartaglione TA; Pieper JA; Lopez LL; Mehta J
    Res Commun Chem Pathol Pharmacol; 1983 Apr; 40(1):15-27. PubMed ID: 6867470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disposition kinetics and urinary excretion of verapamil and some of its primary metabolites after oral administration in patients with angina pectoris.
    Piotrovskii VK; Rumiantsev DO; Nikolenko SA; Riabokon OS; Metelitsa VI
    Int J Clin Pharmacol Ther Toxicol; 1986 Jan; 24(1):4-11. PubMed ID: 3957489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pharmacology of verapamil. V. Tissue distribution of verapamil and norverapamil in rat and dog.
    Hamann SR; Todd GD; McAllister RG
    Pharmacology; 1983; 27(1):1-8. PubMed ID: 6611645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous quantitation of verapamil, norverapamil, and N-dealkylated metabolites in human plasma following oral administration.
    Kapur PA; Law T; Watson E
    J Chromatogr; 1985 Jan; 337(1):160-5. PubMed ID: 3980648
    [No Abstract]   [Full Text] [Related]  

  • 12. Verapamil metabolite exposure in older and younger men during steady-state oral verapamil administration.
    Abernethy DR; Wainer IW; Anacleto AI
    Drug Metab Dispos; 2000 Jul; 28(7):760-5. PubMed ID: 10859149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of metabolites on protein binding of verapamil enantiomers.
    Johnson JA; Akers WS
    Br J Clin Pharmacol; 1995 May; 39(5):536-8. PubMed ID: 7669491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of steady-state verapamil plasma concentrations in children and adults.
    Wagner JG; Rocchini AP; Vasiliades J
    Clin Pharmacol Ther; 1982 Aug; 32(2):172-81. PubMed ID: 7094504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physiological pharmacokinetics and pharmacodynamics of (+/-)-verapamil in female rats.
    Todd EL; Abernethy DR
    Biopharm Drug Dispos; 1987; 8(3):285-97. PubMed ID: 3593905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors affecting the plasma protein binding of verapamil and norverapamil in man.
    Yong CL; Kunka RL; Bates TR
    Res Commun Chem Pathol Pharmacol; 1980 Nov; 30(2):329-39. PubMed ID: 7444161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PBPK modeling to unravel nonlinear pharmacokinetics of verapamil to estimate the fractional clearance for verapamil N-demethylation in the recirculating rat liver preparation.
    Yang QJ; Si L; Tang H; Sveigaard HH; Chow EC; Pang KS
    Drug Metab Dispos; 2015 Apr; 43(4):631-45. PubMed ID: 25650380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Verapamil kinetics in normal subjects and patients with coronary artery spasm.
    Freedman SB; Richmond DR; Ashley JJ; Kelly DT
    Clin Pharmacol Ther; 1981 Nov; 30(5):644-52. PubMed ID: 7297023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of verapamil in patients with renal failure.
    Mooy J; Schols M; v Baak M; v Hooff M; Muytjens A; Rahn KH
    Eur J Clin Pharmacol; 1985; 28(4):405-10. PubMed ID: 4029246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of oral verapamil therapy on antipyrine clearance.
    Rumiantsev DO; Piotrovskii VK; Riabokon OS; Slastnikova ID; Kokurina EV; Metelitsa VI
    Br J Clin Pharmacol; 1986 Nov; 22(5):606-9. PubMed ID: 3790408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.